Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
January 19 2022 - 4:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
January 2022
Commission file number: 001-36288
Akari Therapeutics, Plc
(Translation of registrant's name into English)
75/76 Wimpole Street
London W1G 9RT
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form
40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulations S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulations S-T Rule 101(b)(7): ¨
CONTENTS
On January 19, 2022, Akari
Therapeutics, Plc (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (FDA) agrees
to use of new higher-yielding manufacturing process for nomacopan in pivotal clinical studies
A copy of the press release
is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in paragraphs
one and two of Exhibit 99.1 is hereby incorporated by reference into all effective registration statements filed by the Company under
the Securities Act of 1933.
Exhibit No.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Akari Therapeutics, Plc
|
|
(Registrant)
|
|
|
|
|
|
|
|
By:
|
/s/ Clive Richardson
|
|
|
Name:
|
Clive Richardson
|
|
|
Chief Executive Officer and Chief Operating Officer
|
Date: January 19, 2022
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2023 to Apr 2024